News & Updates

Kyle Kostesich 5/5/22 Kyle Kostesich 5/5/22

Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.

The new name reflects the Company’s growth and evolution, and its goal to become the leading company within oncology therapeutics advancing small molecule immunotherapies.

Kyle Kostesich 4/22/22 Kyle Kostesich 4/22/22

Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute

Kyle Kostesich 3/24/22 Kyle Kostesich 3/24/22

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

Kyle Kostesich 1/4/22 Kyle Kostesich 1/4/22

Phosplatin Therapeutics Appoints Sebastian Guth, PhD, to Board of Directors

Kyle Kostesich 12/14/21 Kyle Kostesich 12/14/21

Phosplatin Therapeutics Announces $37 Million Series A Financing

Kyle Kostesich 11/15/21 Kyle Kostesich 11/15/21

Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma

Kyle Kostesich 9/29/21 Kyle Kostesich 9/29/21

Phosplatin Therapeutics Appoints Industry Veteran Elizabeth Tallett to Board of Directors

Kyle Kostesich 5/20/21 Kyle Kostesich 5/20/21

Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting

Kyle Kostesich 12/7/20 Kyle Kostesich 12/7/20

Phosplatin Therapeutics Presents Phase I Dose Escalation Data of PT-112 in Patients with Relapsed / Refractory Multiple Myeloma at ASH Annual Meeting

Kyle Kostesich 10/27/20 Kyle Kostesich 10/27/20

Phosplatin Therapeutics Announces Data Revealing Novel Mechanistic Attributes for PT-112 at the 32nd EORTC-NCI-AACR Virtual Symposium

Kyle Kostesich 9/18/20 Kyle Kostesich 9/18/20

Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors

Kyle Kostesich 9/9/20 Kyle Kostesich 9/9/20

Phosplatin Therapeutics Announces Two Leadership Appointments

Kyle Kostesich 8/26/20 Kyle Kostesich 8/26/20

Phosplatin Therapeutics Completes $18.4 Million Private Financing Round

Kyle Kostesich 7/23/20 Kyle Kostesich 7/23/20

Phosplatin Therapeutics Receives Notice of US Patent Issuance for PT-112 as Therapeutic Agent for Treatment of Bone or Blood Cancers

Kyle Kostesich 2/18/20 Kyle Kostesich 2/18/20

Phosplatin Therapeutics Announces Publication in OncoImmunology

Kyle Kostesich 2/11/20 Kyle Kostesich 2/11/20

Phosplatin Therapeutics presents positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients at the Genitourinary Cancers Symposium

Kyle Kostesich 11/7/19 Kyle Kostesich 11/7/19

Phosplatin Therapeutics Completes First Fully-Robotic cGMP Drug Product Batch of PT-112 with Baxter BioPharma Solutions’ Halle/Westfalen Germany Facility

Kyle Kostesich 9/29/19 Kyle Kostesich 9/29/19

Phosplatin Therapeutics Convenes Clinical Advisory Board with Prostate Cancer Experts During ESMO 2019 Annual Congress

Kyle Kostesich 10/25/18 Kyle Kostesich 10/25/18

Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma

Kyle Kostesich 10/22/18 Kyle Kostesich 10/22/18

Phosplatin honored at the European Society of Medical Oncology (ESMO) 2018 Annual Meeting